Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Razoxane blocks cell division in the G2/M phase of the cell generation cycle and appears to normalize tumour neovasculature development. These were the principal reasons for the examination and probably for the demonstration of the radiosensitizing activity of Rz. Specially intriguing has been the finding that radiation of primary tumour implants in animals treated with Rz has a powerful potentiating effect on the antimetastatic activity of the combination. This concept has not yet received any clinical examination. Clinical trials with radiotherapy and Rz have demonstrated the clearest beneficial effects in terms of response rates and maintained local control in soft tissue sarcomas and possibly in recurrent rectal and in bladder carcinomas. Interesting heightened activity has also been found in hepatic metastases from gastrointestinal tumours. Carcinomas of the cervix, bronchus and head and neck, however, have not shown any benefit from the combination compared with radiotherapy alone.
 ...
PMID:Radiotherapeutic enhancement by razoxane. 184 74

Two new compounds, 4-[4-[bis-(2-chloroethyl)-amino-]phenyl]-1- hydroxybutane-1,1-bisphosphonic acid (BAD) and aminotris-(methylenephosphonato)-diamminoplatinum(II) (ADP) that both have cytostatic and osteotropic properties, have shown good therapeutic efficacy against an osteosarcoma which metastasizes and kills by lung metastases. We therefore combined each of these drugs with the antimetastic agent razoxane. Razoxane (20 mg/kg i.p., 5 days/week for 6 weeks) was administered in combination with either BAD (30 mg/kg i.p.) or ADP (37.5 mg/kg i.v.) twice weekly for 3 weeks. Tumour volumes, body weight, survival time and occurrence of metastases were recorded, in addition to the measurement of the metastasis area compared to the total lung area in serial histological lung samples. In both experiments, razoxane effected a significant increase in life span while being ineffective in tumour inhibition. Razoxane in combination with BAD displayed an enhanced anticancer activity which was not significant. ADP had a good antineoplastic activity and a large increase in survival time (144 per cent ILS). Razoxane used in combination with ADP did not influence antitumour efficacy. Median survivals of both ADP-treated groups were significantly longer than the razoxane-treated group. Analysis of the lung metastasis area showed a maximum of 57 per cent for the controls while all treated groups occupied a lesser area. The lowest metastases area was found with the combination treatment BAD + RAZ (18 per cent). This was considered an antimetastatic effect, while ADP treatment effected a time delay only. No change in metastatic pattern was observed in any of the treatment groups. Histological examination showed no effect on the capillaries in the proliferating region of the tumours that could account for the lower occurrence of metastases.
Clin Exp Metastasis
PMID:Therapeutic efficacy of two different cytostatic-linked phosphonates in combination with razoxane in the transplantable osteosarcoma of the rat. 235 Sep 20

The cytostatic and antimetastatic activities of 1,2-di(3,5-dioxopiperazin-1-yl) propane (ICRF-159, razoxane) were studied in a transplantable, slowly growing osteosarcoma in Sprague-Dawley rats. This tumor model is characterized by osteoid formation and spontaneous metastasization to lungs, kidneys and lymph nodes. Razoxane given intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation (30 mg/kg or 10 mg/kg per day) resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor. Early treatment with razoxane (30 mg/kg i.p. from day -2 to +14) showed a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation). Whereas 59.9 per cent of the total sectional area of the lungs in the control animals was covered by osteosarcoma metastases, only 3.4 per cent and 26.1 per cent respectively was affected in the early and late razoxane treatment groups. Toxic side-effects of these treatment schedules were reversible diffuse alopecia, but no retardation of body weight gain.
Clin Exp Metastasis
PMID:Antimetastatic effects of razoxane in a rat osteosarcoma model. 347 Jan 64

Three Lewis lung carcinoma lines (3LL) with different metastatic behavior have been investigated with regard to their response to Razoxane (ICRF-159). The effects of different schedules were tested both on primary and secondary tumors. Results show that the lines are heterogeneous in their response to this antimetastatic agent and that, in particular, BM21548 the least metastatic line is also less sensitive to ICRF-159. A better response can be achieved with this line by a proper fractionation regimen which takes into account the delayed metastasis release from primary tumor. As far as M1087, the most metastatic line is concerned, secondaries are greatly affected by ICRF-159 treatment if performed at a moderately advanced stage of growth. On the contrary, metastases from early tumor stages can be better controlled by radical surgery of the primary implant than by treatment with ICRF-159.
 ...
PMID:Lewis lung carcinoma lines with different metastatic behavior: response to ICRF-159. 671 81